Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CHF | -.--% | -27.92% | -62.93% |
Apr. 11 | Syncona to Sell Stake in Portfolio Company to Century Therapeutics | MT |
Feb. 20 | Syncona’s Takeover of Freeline Therapeutics Becomes Effective | MT |
Sales 2016 | 14.68M 13.41M | Sales 2017 | 14.57M 13.31M | Capitalization | 105M 95.69M |
---|---|---|---|---|---|
Net income 2016 | -29M -26.49M | Net income 2017 | - 0 | EV / Sales 2016 | 17.6 x |
Net cash position 2016 | 12.69M 11.59M | Net cash position 2017 | 21.39M 19.53M | EV / Sales 2017 | 5.72 x |
P/E ratio 2016 |
-9.21
x | P/E ratio 2017 |
-70
x | Employees | - |
Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 47.9% |
Managers | Title | Age | Since |
---|---|---|---|
Peter McCormack
DFI | Director of Finance/CFO | 45 | 09-12-31 |
Bruce Jackson
CTO | Chief Tech/Sci/R&D Officer | 55 | 13-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Leonardo de Luca
BRD | Director/Board Member | - | - |
1st Jan change | Capi. | |
---|---|---|
-62.93% | 0 | |
+5.58% | 82.93B | |
+3.69% | 76.85B | |
-14.62% | 53.04B | |
-24.56% | 46.55B | |
+31.16% | 50.15B | |
+17.75% | 41.41B | |
+55.21% | 35.63B | |
-10.24% | 24.64B | |
-21.24% | 23.04B |
- Stock Market
- Equities
- MYRN Stock